October 22, 2024
Oral semaglutide (Rybelsus) lowered the risk for major adverse cardiovascular events (MACEs) by a significant 14% compared with placebo, Novo Nordisk announced. The topline results met […]
October 22, 2024
(Reuters) – The U.S. Food and Drug Administration has declined to approve Camurus’ drug for the treatment of a rare hormonal disorder due to deficiencies at […]
October 21, 2024
When prescribing glucagon-like peptide 1 (GLP-1) medications, many physicians prefer tirzepatide over the more well-known semaglutide due to its superior efficacy in weight loss and A1c […]
October 21, 2024
TOPLINE: In healthy young adults, a single 30-minute bout of outdoor aerobic exercise significantly reduces fasting and 1-hour glucose levels during an oral glucose tolerance test […]
October 21, 2024
(Reuters) – Eli Lilly said on Monday it sued three medical spas and online vendors for selling products claiming to contain tirzepatide, the main ingredient in […]
October 18, 2024
TOPLINE: Patients who achieved an A1c level < 6.5% after metabolic bariatric surgery (MBS) maintained this target in the short and long terms, regardless of whether […]
October 17, 2024
Medtronic has issued a second alert letter to patients regarding shortened battery life of the MiniMed 600 and 700 series insulin pumps. The affected products include […]
October 17, 2024
TOPLINE: Children with obesity and metabolic dysfunction–associated steatotic liver disease (MASLD) have a higher risk for youth-onset type 2 diabetes (T2D), and the risk increases dramatically […]
October 16, 2024
Katie Sullivan, DNP, FNP-C, is publicizing her own challenge with updating an insulin pump as part of an effort to bring an end to the biannual […]